Influence of IGF1 (insulin-like growth factor 1) signaling pathway to the development of cancer diseases
Authors:
R. Kučera 1; O. Topolčan 1; O. Fiala 2; V. Šimánek 1
Authors place of work:
Oddělení nukleární medicíny, Imunoanalytická laboratoř, FN a LF v Plzni, Univerzita Karlova v Praze
1; Onkologická klinika, FN a LF v Plzni, Univerzita Karlova v Praze
2
Published in the journal:
Klin. Biochem. Metab., 24, 2016, No. 1, p. 20-26
Summary
The influence of IGF1 (insulin-like growth factor 1) and its binding proteins to the cancer incidence and development have been discussed recently. Since the early 80’s of the last century, many experiments and studies were carried out on this topic. These findings allow us to give an idea about the functioning of IGF1 and its role in the growth, differentiation and cell surviving. Our knowledge ultimately resulted in the development of the latest generation of oncological drugs. Despite of major achievements in research of IGF1, its place in tumor diagnosis is currently not so clear.
Keywords:
Insulin-like growth factors, binding proteins, receptors, cancer development.
Zdroje
1. Peterson, J. E., Kulik, G., Jelinek, T., Reuter, C. W., Shannon, J. A., Weber, M. J. Src phosphorylates the insulin-like growth factor type I receptor on the autophosphorylation sites. Requirement for transformation by src. J Biol. Chem., 1996, Dec 6, 271(49), p. 31562–31571.
2. Schnarr, B., Strunz, K., Ohsam, J., Benner, A., Wacker, J., Mayer, D. Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer. Int. J Cancer., 2000, 89, p. 506–513.
3. Le Marchand, L., Wang, H., Rinaldi, S., Kaaks, R., Vogt, T. M., Yokochi, L., Decker, R. Associations of plasma C-peptide and IGFBP-1 levels with risk of colorectal adenoma in a multiethnic population. Cancer Epidemiol. Biomarkers Prev., 2010, 19(6), p. 1471-7.
4. Flood, A., Mai, V., Pfeiffer, R., Kahle, L., Remaley, A. T., Rosen, C. J., Lanza, E., Schatzkin, A. The effects of a high-fruit and -vegetable, high-fiber, low-fat dietary intervention on serum concentrations of insulin, glucose, IGF-I and IGFBP-3., Eur. J Clin. Nutr., 2008, Feb 62(2), p. 186-196.
5. Santoro, M. A., Andres, S. F., Galanko, J. A., Sandler, R. S., Keku, T. O., Lund, P. K. Reduced insulin-like growth factor I receptor and altered insulin receptor isoform mRNAs in normal mucosa predict colorectal adenoma risk. Cancer Epidemiol. Biomarkers Prev., 2014, 23(10), p. 2093-100.
6. Allison, A. S., McIntyre, M. A., McArdle, C., Habib, F. K. The insulin-like growth factor type 1 receptor and colorectal Neoplasia: insights into invasion, Hum. Pathol., 2007, Nov 38(11), p. 1590-602.
7. Renehan, A. G., Brennan, B. M. Acromegaly, growth hormone and cancer risk., Best Pract. Res. Clin. Endocrinol. Metab., 2008, 22(4), p. 639-57.
8. Baglietto, L., English, D. R., Hopper, J. L., Morris, H. A., Tilley, W. D., Giles, G. G. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiol. Biomarkers, 2007, 16(4), p. 763-8.
9. Rinaldi, S. et al. IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr. Relat. Cancer, 2006,13(2), p. 593-605.
10. Sakauchi, F., Nojima, M., Mori, M., Wakai, K., Suzuki, S., Tamakoshi, A., Ito, Y., Watanabe, Y., Inaba, Y., Tajima, K., Nakachi, K. Serum insulin-like growth factors I and II, insulin-like growth factor binding protein-3 and risk of breast cancer in the Japan Collaborative Cohort study. Asian Pac. J Cancer., 2009, 10 Suppl, p. 51-5.
11. Chen, W., Wang, S., Tian, T., Bai, J., Hu, Z., Xu, Y., Dong, J., Chen, F., Wang, X., Shen, H. Phenotypes and genotypes of insulin-like growth factor 1, IGF-bin-ding protein-3 and cancer risk: evidence from 96 studies. Eur. J Hum. Genet., 2009 Dec 17(12), p. 1668-75.
12. Schernhammer, E. S., Holly, J. M., Hunter, D. J., Pollak, M. N., Hankinson, S. E. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr. Relat. Cancer., 2006, 13(2), p. 583-92.
13. Maor, S., Yosepoxich, A. et al. Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast cancer tumours associated with BSCA1 mutations., Cancer Lett., 2007, 257, p. 236-43.
14. Chapman, J. A., Pritchard, K. I., Goss, P. E., Ingle, J. N., Muss, H. B., Dent, S. F., Vandenberg, T. A., Findlay, B., Gelmon, K. A., Wilson, C. F., Shepherd, L. E., Pollak, M. N. Competing risks of death in younger and older postmenopausal breast cancer patients. World J Clin. Oncol., 2014, Dec 10, 5(5), p. 1088-96.
15. Monti, S., Proietti-Pannunzi, L., Sciarra, A., Lolli, F., Falasca, P., Poggi, M., Celi, F. S., Toscano, V. The IGF axis in prostate cancer., Curr. Pharm. Des., 2007, 13, p. 719-27
16. Djavan, B., Bursa, B., Seitz, C., Soeregi, G., Remzi, M., Basharkhah, A., Wolfram, R., Marberger, M. Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection., Urology, 1999, 54(4), p. 603-6.
17. Rowlands, M. A., Gunnell, D., Harris, R., Vatten, L. J., Holly, J. M., Martin, R. M. Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int. J Cancer., 2009, 124(10), p. 2416-29.
18. Nickerson, T., Chang, F., Lorimer, D., Smeekens, S. P., Sawyers, C. L., Pollak, M. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res., 2001, 61(16), p. 6276–6280.
19. Ryan, C. J., Haqq, C. M., Simko, J., Nonaka, D. F., Chan, J. M., Weinberg, V., Small, E. J., Goldfine, I. D. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer. Urol. Oncol., 2007, 25(2), p. 134-40.
20. Chen, B., Liu, S., Xu, W., Wang, X., Zhao, W., Wu, J. IGF-I and IGFBP-3 and the risk of lung cancer: a meta-analysis based on nested case-control studies. J Exp. Clin. Cancer Res., 2009, 24, p. 28-89.
21. Linnerth, N. M., Siwicky, M. D., Campbell, C. I., Watson, K. L., Petrik, J. J., Whitsett, J. A., Moorehead, R. A. Type I insulin-like growth factor receptor induces pulmonary tumorigenesis. Neoplasia, 2009, 11(7), p. 672-82.
22. Dilli, U. D., Yildırim, M., Suren, D., Alikanoglu, A., Kaya, V., Goktas, S., Yildiz, M., Sezer, C., Gunduz, S. Lack of any prognostic role of insulin-like growth factor-1 receptor in non-small cell lung cancer. Asian Pac. J. Cancer Prev., 2014, 15(14), p. 5753-7.
23. Kucera, R., Treskova, I., Vrzalova, J., Svobodova, S., Topolcan, O., Fuchsova, R., Rousarova, M., Treska, V., Kydlicek, T. Evaluation of IGF1 serum levels in malignant melanoma and healthy subjects. AntiCancer Res., 2014, Sep 34(9), p. 5217-20.
24. Lewis, D. A., Travers, J. B., Somani, A. K., Spandau, D. F. The IGF-1/IGF-1R signaling axis in the skin: a new role for the dermis in aging-associated skin cancer. Oncogene, 2010, 29(10), p. 1475-85.
25. Peeters, P. H., Lukanova, A., Allen, N., Berrino, F., Key, T. et al. Serum IGF-I, its major binding protein (IGFBP-3) and epithelial ovarian cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr. Relat. Cancer., 2007, 14(1), p. 81-90.
26. Gotlieb, W. H., Bruchim, I., Gu, J., Shi, Y., Camirand, A., Blouin, M. J., Zhao, Y., Pollak, M. N. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. Gynecol. Oncol., 2006, 100(2), p. 389-96.
27. Steller, M. A., Delgado, C. H., Bartels, C. J., Woodworth, C. D., Zou, Z. Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res., 1996, 56(8), p. 1761-5.
28. Mathur, S. P., Mathur, R. S., Gray, E. A., Lane, D., Underwood, P. G., Kohler, M., Creasman, W. T. Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-A. Gynecol. Oncol., 2005, 98(3), p. 467-83.
29. Yi, H. K., Hwang, P. H., Yang, D. H., Kang, C. W., Lee, D. Y. Expression of the insulin-like growth factors (IGFs) and the IGF-binding proteins (IGFBPs) in human gastric cancer cells. Eur J Cancer., 2001, 37, p. 2257–2263.
30. Kaseb, A. O., Abbruzzese, J. L., Vauthey, J. N., Aloia, T. A., Abdalla, E. K., Hassan, M. M., Lin, E., Xiao, L., El-Deeb, A. S., Rashid, A., Morris, J. S. I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score. Oncology, 2011, 80(5-6), p. 373-81.
31. Su, W. W., Lee, K. T., Yeh, Y. T., Soon, M. S., Wang, C. L., Yu, M. L., Wang, S. N. Association of circulating insulin-like growth factor 1 with hepatocellular carcinoma: one cross-sectional correlation study. J Clin. Lab. Anal., 2010, 24, p. 195–200.
32. Gray, S. G., Eriksson, T., Ekström, C., Holm, S., von Schweinitz, D., Kogner, P., Sandstedt, B., Pietsch, T., Ekström, T. J. Altered expression of members of the IGF-axis in hepatoblastomas. Br. J Cancer., 2009, 82(9), p. 1561-7.
33. Wolpin, B. M., Michaud, D. S., Giovannucci, E. L., Schernhammer, E. S., Stampfer, M. J., Manson, J. E., Cochrane, B. B., Rohan, T. E., Ma, J., Pollak, M. N., Fuchs, C. S. Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts. Br. J Cancer., 2007, Jul 2, 97(1), p. 98-104.
34. Stolzenberg-Solomon, R. Z., Limburg, P., Pollak, M., Taylor, P. R., Virtamo, J., Albanes, D. Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers. Cancer Epidemiol. Biomarkers Prev., 2004, Mar 13 (3), p. 438-44.
35. Chakravarty, G., Santillan, A. A., Galer, C., Adams, H. P., El-Naggar, A. K., Jasser, S. A., Mohsin, S., Mondal, D., Clayman, G. L., Myers, J. N. Phosphorylated insulin like growth factor-I receptor expression and its clinico-pathological significance in histologic subtypes of human thyroid cancer. Exp. Biol. Med., 2009, 234(4), p. 372-83.
Štítky
Clinical biochemistry Nuclear medicine Nutritive therapistČlánok vyšiel v časopise
Clinical Biochemistry and Metabolism
2016 Číslo 1
Najčítanejšie v tomto čísle
- Antibody structure and its reactivity.
- Criteria of analytical quality measurement in clinical biochemistry. Current international consensus and its implications for routine action of clinical laboratories.
- Influence of IGF1 (insulin-like growth factor 1) signaling pathway to the development of cancer diseases
- IGF1 (insulin-like growth factor 1), basic characteristics, biological effect, age and gender dependence